利福平羧甲基壳聚糖的制备及性能研究

Preparation and Capability Studies of Rifampicin/CMC

选择生物相容性好,可生物降解的羧甲基壳聚糖为药物载体,并通过体外抗菌试验,从载体的自身结构和释药过程2个方面,对其结构进行了测定和分析。结果表明,所合成的利福平羧甲基壳聚糖体系,具有一定缓释性能,符合临床使用要求,可作为新型缓释药物临床应用。

Choosing the biodegradable and biocompatible Carboxymethyl Chitosan（CMC） as the medicament carrier. To analyze and test its structure, we carry on a series of antimicrobial test in vitro on two aspects about the medicament carrier＇s structure and release process. The result shows that Rifampicin/CMC system has a certain sustained release capability and reaches the clinic using standard, so that it could be used as a new type sustained release medicine in clinic.